# Zacks

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/zacks-company
Canonical HTML page: https://getyourbrief.com/entity/zacks-company

## Recent coverage (7 stories, network-wide)

### NBP & CRMZ Micro-Cap Earnings: $(0.16) vs $(0.04) EPS
2026-08-22 07:00:25 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Two micro-caps reported late-August earnings: biotech I-Mab posted $(0.16) EPS while CreditRiskMonitor posted $(0.04) EPS on $5.17M revenue. Divergent risk profiles—1.47 beta vs 0.22 beta—highlight small-cap earnings dynamics.
Full story: https://getfinancebrief.com/story/imab-creditriskmonitor-microcap-earnings-comparison

### I-Mab Posts $(0.16) EPS; $9 PT Implies 371% Upside
2026-08-22 07:00:16 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Full story: https://getbiobrief.com/story/imab-nbp-q3-2026-earnings-biotech-analysis

### SENEA EPS miss overshadowed by 24% revenue beat; TALK misses both lines
2026-08-12 14:54:56 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Seneca Foods posted a top-line beat of $405.17M, 24% above estimates, despite a $0.07 EPS miss, driving a 7.4% stock surge and Strong Buy ratings. Talkspace, meanwhile, missed on both EPS and revenue, but its stock held steady as institutional investors continued accumulating shares.
Full story: https://getfinancebrief.com/story/seneca-foods-talkspace-earnings-analysis-q2-2026

### Atlanticus EPS Beats by $0.08 as Insiders Sell $7.9M in Stock
2026-08-09 17:05:12 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Atlanticus Holdings (ATLC) delivered a $2.50 EPS, beating by $0.08, on solid profitability metrics. Simultaneously, insiders including the CFO sold $7.87 million in shares, raising questions about alignment. With a P/E of 16.69 and beta of 2.11, the stock remains a volatile play in consumer credit.
Full story: https://getfinancebrief.com/story/atlanticus-earnings-insider-selling-7-9m

### Aligos Therapeutics Beats Q2 Consensus by $0.95 EPS, Signaling Clinical Momentum
2026-08-09 17:05:04 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Aligos Therapeutics (ALGS) handily beat Q2 consensus earnings per share by $0.95, a significant outperformance for the clinical-stage biotech. This beat may reflect operational efficiencies, milestone payments, or clinical progress in its liver disease pipeline. Investors in the biotech space should watch for full financial disclosures to gauge the sustainability of this positive surprise.
Full story: https://getbiobrief.com/story/aligos-earnings-beat-0-95-eps

### CPKC's $2.93B quarterly revenue signals 12.6% growth for North American freight
2026-08-03 17:03:01 · Sector: supply · Sentiment: Neutral · Impact: 6/10 · Sources: 2

CPKC's Q2 earnings beat, with revenue up 12.6% to $2.93 billion, highlights robust cross-border rail demand. For supply chain professionals, the performance reflects strong trade flows and network integration benefits post-merger.
Full story: https://getsupplybrief.com/story/cpkc-q2-2026-supply-chain-impact

### CPKC beats Q2 estimates with $0.92 EPS; analysts see 16% upside to $105
2026-08-03 17:02:51 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Canadian Pacific Kansas City posted a $0.03 EPS beat and 12.6% revenue growth, maintaining strong margins. With a consensus Buy rating and price targets as high as $105, the stock offers a defensive growth story for investors.
Full story: https://getfinancebrief.com/story/cpkc-q2-2026-earnings-beat-finance

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.